Drug intelligence / Profile preview

anti-CD71 antibody

Development stage
Unknown
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous, Subcutaneous, Intralesional
01

Overview

An **anti-CD71 antibody** is a monoclonal antibody designed to target CD71, also known as transferrin receptor 1 (TfR1). CD71 is a membrane glycoprotein that plays a critical role in cellular iron uptake via the endocytosis of iron-bound transferrin. Because rapidly proliferating cells, such as cancer cells, have high iron requirements, CD71 is frequently overexpressed in various hematologic and solid malignancies. Anti-CD71 antibodies can inhibit cell proliferation by blocking iron import or can be utilized as targeting moieties in antibody-drug conjugates (ADCs) and Probody-drug conjugates (PDCs), such as CX-2029 and INA03, to deliver cytotoxic payloads directly to tumor cells. Additionally, anti-CD71 antibodies are used in preclinical research to investigate iron metabolism, erythropoiesis, and tissue regeneration, including localized bone marrow erythropoiesis and oxygen regulation during fracture healing [1].

Other names
anti-CD71 monoclonal antibodyanti-CD-71 monoclonal antibodyanti-CD 71 monoclonal antibodyanti-TfR1 antibodyanti-TfR-1 antibodyanti-TfR 1 antibodyanti-transferrin receptor 1 antibodyanti-transferrin receptor antibody
02

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on anti-CD71 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD71 antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call